top of page
Browse by category
Search


Rejuva GLP-1-based pancreatic gene therapy candidate results in greater weight loss vs. semaglutide
Fractyl Health has revealed preclinical findings from its Rejuva gene therapy platform at the European Association for the Study of...


Journal Watch 4/10/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


Researchers find target for prompting fat cells to expend energy
Researchers at the University of Colorado School of Medicine have identified a potential target for treating obesity and metabolic...


How bariatric surgery reduces the risk of developing cardiovascular disease
In patients living with obesity, low-density lipoprotein (LDL) does not function normally increasing the risk of cardiovascular disease...


Structure announces positive results from oral GLP-1 receptor agonist gsbr-1290
Structure Therapeutics has announced positive results from the Phase 1b multiple ascending dose (MAD) study of its highly selective oral...


Kallyope initiates study assessing new oral nutrient receptor agonists for the treatment of obesity
Kallyope has initiated a Phase 2 trial evaluating K-757 and K-833, new oral nutrient receptor agonists being studied for obesity and Type...


A wasted decade: Access to weight management interventions in England stagnate
Access to weight management (WM) interventions in England has not improved over the last ten years despite obesity rates continuing to...


Genetics can predict and help improve outcomes after bariatric surgery
Clinicians treating severe obesity have a new genetic tool for predicting and ultimately improving bariatric surgery outcomes, according...


NICE draft guidance approves of ESG as an option to treat obesity
The UK’s National Institute for Health and Care Excellence (NICE) has issued draft guidance stating that endoscopic sleeve gastroplasty...


European Medicines Agency to discuss anaesthesia risk for weight-loss drugs
The European Medicines Agency (EMA) will assess the risk that patients on weight loss drugs such as semaglutide and tirzepatide may...
Browse by tag






bottom of page